CC 90011

Drug Profile

CC 90011

Alternative Names: CC90011

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 30 Aug 2016 Preclinical trials in Non-Hodgkin's lymphoma in USA (PO) before August 2016
  • 30 Aug 2016 Preclinical trials in Solid tumours in USA (PO) before August 2016
  • 30 Aug 2016 Celgene plans a phase I trial for Solid tumours and Non-Hodgkin's lymphoma in France and United Kingdom (NCT02875223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top